What Should I Do About High Iron on TRT? (TRT Q&As)
Timeline
Dr. O’Connor reviews the member’s CBC, testosterone, SHBG, calcium, and iron results and says additional information is needed, particularly ferritin and the complete clinical history. He cautions against automatically using phlebotomy because unnecessary blood removal could lower hemoglobin and deplete iron stores.
Dr. O’Connor explains that androgens commonly suppress SHBG, which can increase free testosterone and alter how the laboratory numbers appear. He says there is generally no reason to specifically raise SHBG and instead focuses on symptoms, free testosterone, and broader health markers.
Dr. O’Connor discusses the member’s relatively high testosterone exposure and aromatase inhibitor use as possible contributors. He suggests reducing the testosterone dose, reconsidering the AI, and evaluating other causes of sleep and anxiety symptoms rather than trying to manage laboratory estrogen numbers alone.
Dr. O’Connor says acne responses to androgens are highly influenced by genetics and can be unpredictable between cycles. He cautions against using aromatase inhibitors simply to control acne and notes that severe cystic acne may require direct dermatologic treatment.
Dr. O’Connor explains that beginning testosterone young can suppress natural production and potentially become a lifelong commitment. He discusses fertility, testicular atrophy, hair loss, gynecomastia, acne, cardiovascular and prostate considerations, and the importance of understanding those tradeoffs before starting.
A 53-year-old man using 150 mg of testosterone every five days reports blood pressure around 128/85 and asks whether lowering his dose could help. Dr. O’Connor supports reducing the testosterone exposure and also questions the need for 1 mg of anastrozole every five days, emphasizing a more sustainable regimen and cardiovascular monitoring.
Video Summary
This mailbag discussion focuses on questions linking sleep quality with response to testosterone therapy. It explains how inadequate sleep and circadian disruption can blunt symptom improvement despite appropriate dosing. Sleep is framed as a foundational modifier of therapeutic response.
A central portion explores recovery physiology, including how poor sleep can amplify fatigue, mood changes, and training intolerance.
The episode emphasizes distinguishing hormonal issues from sleep-driven symptoms. Contextual evaluation is highlighted to avoid unnecessary protocol changes.
The closing segment integrates sleep optimization into long-term testosterone management. Expectation alignment, routine consistency, and recovery awareness are emphasized. Hormone therapy is positioned as interacting closely with sleep health rather than operating independently.
Drug Callouts
Condition Callouts
Key Takeaways
- Sleep quality strongly influences perceived testosterone therapy benefit.
- Poor recovery can mimic inadequate hormone response.
- Circadian alignment supports symptom stability.
- Evaluating sleep prevents unnecessary treatment changes.
- Integrated recovery awareness improves long-term outcomes.